pokerbrosrealmoney| Shanghai Pharmaceutical: The subsidiary company's metoclopramide hydrochloride injection passed consistency evaluation

News summary

[Shanghai Pharmaceuticalpokerbrosrealmoney: Subsidiary company Metoclopramide Hydrochloride Injection passed consistency evaluation] Securities Times e Company Newspokerbrosrealmoney, Shanghai Pharmaceutical (601607) announced on the evening of May 16 that recently, Shanghai Hefeng Pharmaceutical, a controlling subsidiary of the company, received a report from the State Food and Drug Administration on metoclopramide hydrochloride injection.pokerbrosrealmoney.pokerbrosrealmoney..

Newsletter text

[Shanghai Pharmaceutical: Subsidiary Metoclopramide Hydrochloride Injection Passed Consistency Evaluation] Securities Times e Company News, Shanghai Pharmaceutical (601607) announced on the evening of May 16 that recently, the company's controlling subsidiary Shanghai Hefeng Pharmaceutical received The "Drug Supplement Application Approval Notice" issued by the State Food and Drug Administration on Metoclopramide Hydrochloride Injection has passed the consistency evaluation of generic drug quality and efficacy. Metoclopramide hydrochloride injection is mainly used to relieve emetics.